A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test

Psoriasis Clinical Trial

Official title:

A Phase I, Randomized, Observer-blind, Single-center, Vehicle- And Comparator-controlled, Initial Dose-ranging Study To Assess The Antipsoriatic Efficacy Of Different Concentrations Of An2728 Cream In A Psoriasis Plaque Test

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00763204
• Other study ID #: AN2728-PSR-103
• Secondary ID: 2007-006600-37C3
• Status: Completed
• Phase: Phase 1
• Start date: February 29, 2008
• Est. completion date: March 7, 2008

Study information

• Verified date: February 2019
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate dose-response relationship, antipsoriatic efficacy and safety of different concentrations of topical formulations with AN2728 in subjects with psoriasis vulgaris.

Description:

The study will be performed in 12 male subjects with stable psoriatic plaques. The study preparations and the comparator will be tested observer-blind. Treatments will be randomly assigned to the test fields. All subjects will receive all treatments, with intraindividual comparison of the treatments.

Altogether six test fields will be examined per subject (four active AN2728 creams of different concentrations: 2 %, 1 %, 0.3 %, 0.03 %, the active ingredient-free vehicle, and a marketed corticoid preparation). The test fields will be treated occlusively over a study period of 12 days. Topical application of approximately 200 uL of each assigned intervention is administered per treatment, for a total of 10 treatments over a 12-day treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: March 7, 2008
• Est. primary completion date: March 7, 2008
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• male subjects aged 18 years or older

• subjects with psoriasis vulgaris in a chronic stable phase and stable plaques with an area sufficient for five treatment fields

• the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study

• written informed consent obtained

Exclusion Criteria:

• subjects with psoriasis guttata or pustular psoriasis

• subjects who require systemically acting medications for the treatment of psoriasis, which might counter or influence the study objectives, e.g. corticosteroids, cytostatics

• local treatment with antipsoriatics (like vitamin D, dithranol, glucocorticosteroids; except for salicyclic acid in vaseline) in the 4 weeks preceding and during the study; and any antipsoriatic treatment on the plaques (including corticosteroids, except for salicyclic acid) in the 8 weeks preceding and during the study.

• systemic treatment with antipsoriatics in the three months preceding and during the study

• treatment with systemic or locally acting medications which might counter or influence the study aim (e.g. MAO inhibitors, anti-epileptic drugs, anti-psychotic drugs) or medications which are known to provoke or aggravate psoriasis, e.g. Beta-blocker, antimalarial drugs and lithium drugs within two weeks before the beginning of the study and during the study.

• known allergic reactions to the active ingredients or other components of the study preparations or comparators

• blood pressure and heart rate outside the following allowed ranges: systolic blood pressure 80-160 mm Hg, diastolic blood pressure 60 - 100 mm Hg, heart rate 40-120 beats/min

• evidence of drug abuse

• UV-therapy within 4 weeks before beginning and during the study

• Symptoms of a clinically significant illness that may influenced the outcome of the study in the 4 weeks before and during the study

• participation in another clinical trial involving pharmaceutical products in the 4 weeks preceding and during the study

• in the opinion of the investigator or physician performing the initial examination the patient should not participate in the study, e.g. due to probable noncompliance or inability to understand the study and give adequately informed consent

• subject is institutionalized because of legal or regulatory order

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• AN2728 Cream, 2%

• AN2728 Cream, 1%

• AN2728 Cream, 0.3%

• AN2728 Cream Vehicle

• Betnesol®-V Creme, 0.1%

Locations

Country	Name	City	State
Germany	Bioskin GmbH	Hamburg

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of the active study preparations compared to the corresponding vehicle using differences in infiltrate thickness on study day 12.		Day 12
Secondary	Change in infiltrate thickness		Day 8
Secondary	Sonographic measurements of infiltrate thickness		Day 8, Day 12
Secondary	The AUC of the infiltrate thickness		Day 8, Day 12
Secondary	Clinical assessment scores for assessment of efficacy		Day 8, Day 12